BRCA1 and breast cancer: Moreover, we observed that breast cancer cells with BRCA1 mutation and ZNF251KD (BRCA1mut + ZNF251KD) were not only resistant to various PARPis, but also to platinum-based drugs and DNA polymerase theta (Polθ) inhibitors.